[Secondary prevention after ischemic cerebral infarct. The ESPRIT Study: low dose anticoagulation, combined therapy with acetylsalicylic acid/dipyridamole or monotherapy with acetylsalicylic acid?].
The European and Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) is a randomised clinical trial in which patients with cerebral ischaemia of arterial origin will be randomised between oral anticoagulation (international normalized ratio (INR): 2.0-3.0), the combination of acetylsalicylic acid (in any dose between 30 and 325 mg per day) plus dipyridamole (400 mg daily) and acetylsalicylic acid only (in any dose between 30 and 325 mg per day). It is planned to enroll 4500 patients with a mean follow-up of three years. Primary outcome is the composite event of vascular death, stroke, myocardial infarction, or major bleeding complication; outcome assessment will be blinded. ESPRIT is an international, multi-center study in which 60-80 hospitals in the Netherlands and other countries in Europe and Australia will participate.
Gorter
J W
JW
Trial Bureau Neurologie, Universitätsklinikum Utrecht, Niederlande.
De Schryver
E L
EL
Algra
A
A
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D001315:Australia; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000401:mortality; D004176:Dipyridamole / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005060:Europe; D005500:Follow-Up Studies; D006801:Humans; D012008:Recurrence; D015996:Survival Rate; D016896:Treatment Outcome
D000925:Anticoagulants; D004176:Dipyridamole; D001241:Aspirin